Could treatments with beta-blockers be associated with a reduction in cancer risk?;Les traitements par β-bloquants pourraient-ils être associés à une diminution du risque de cancer?

Revue d'Epidemiologie et de Sante Publique

Volumn 52, Issue 1, 2004, Pages 53-65

  Algazi, M ^a   Plu Bureau, G ^b   Flahault, A ^c   Dondon, M G ^d   Le M G ^d  

^a Hôpital Privé des Diaconesses   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Beta blockers; Cancer; Cohort Study

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DRUG EXPOSURE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; FRANCE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION;

EID: 1842781211     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0398-7620(04)99022-0     Document Type: Article

References (31)

1. Jick H, Jick S, Derby LE, Vasilakis C, Wald Lyers M, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
2. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlick RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-9.
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12.
4. Fletcher AE, Beevers DG, Bulpitt CJ, et al. Cancer mortality and atenolol treatment. BMJ 1993; 306: 622-3.
5. Hole DJ, Hawthorne VM, Isles CG, et al. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306: 609-11.
6. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 239: 1145-51.
7. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279: 1000-4.
8. UK Prospective Diabetes Study Group. Efficacity of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20.
9. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992; 3: 323-31.
10. Ménégoz F, Chérié-Challine L, et Réseau Francim. Le cancer en France: incidence et mortalité. Situation en-1995 et évolution entre 1975 et 1995. Paris: La Documentation Française, Paris: 1998.
11. Legleye S. Géographie des consommations d'alcool en France. Rev Épidemiol Sante Publ 2002; 50: 547-59.
12. Vari J, Martinez-Gonzalez M, Martinez J. Obesity prevalence in Europe. An Sist Sanit Navar 2002; 25: 103-8.
13. Talbot-Smith A, Fritschi L, Diviniti ML, Mallon DF, Knuiman MW. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003; 157: 606-12.
14. Vandentorren S, Baldi I, Annesi Maesano I, et al. Long-term mortality among adults with or without asthma in the PAARC study. Eur Respir J 2003; 21: 462-7.
15. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-52.
16. Felmeden DC, Lip GYH. Antihypertensive therapy and cancer risk. Drug Safety 2001; 24: 727-39.
17. Vandewalle B, Revillon F, Lefebvre J. Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 1990; 116: 303-6.
18. Nagmani R, Pasco DS, Salas RD, Feller DR. Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. Biochem Pharmacol 2003; 65: 1489-94.
19. Weddle DL, Tihoff P, Williams M, Shuller HM. β-adenergic growth regulation of human cancer cell lines from pancreatic ductal carcinomas. Carcinogenesis 2001; 22: 473-9.
20. Chan HC, Fong SK, Chung YW, Wong PY. Stimulation of anion secretion by beta-adrenoceptors in the mouse endometrial epithelium. J Physiol 1997; 501: 517-25.
21. Masur K, Niggeman B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells inhibited by beta-blockers. Cancer Res 2001; 61: 2866-9.
22. Shakhar G, Ben-Eliyahu S. In vivo β-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998; 160: 3251-8.
23. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000; 8: 154-64.
24. Cohen M, Klein E, Kuten A, Fried G, Zinder O, Pollack S. Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevate levels of stress hormones and decreased secretion of Th1 cyto. Int J Cancer 2002; 100: 347-54.
25. Fourneret P, Desombre H, de Villard R, Revel O. Interest of propanolol in the treatment of school refusal anxiety: about clinical observations. Encephale 2002; 27: 578-84.
26. Zonderman AB. Depression as a risk for cancer morbidity and mortality in a nationnally representative sample. JAMA 1989; 262: 1191-5.
27. Jasmin C, Lê MG, Marty P, Herzberg R, and the Psycho-Oncologic Group (POG). Evidence for a link between certain psychological factors and the risk of breast cancer in a case-control study. Ann Oncol 1990; 1: 22-9.
28. Graham J, Ramirez A, Love S, Richards M, Burgess C. Stressful life experiences and risk of relapse of breast cancer: observational cohort study. BMJ 2002; 324: 1420-8.
29. Walters MR, Sharma R. Cross-talk between beta-adrenergic stimulation and estrogen receptors: isoproterenol inhibits 17beta-estradiol-induced gene transcription in A7r5 cells. J Cardiovasc Pharmacol 2003; 42: 266-74.
30. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31.
31. Bouyer J, Hémon D, Cordier S, et al. Stratégie d'analyse des enquêtes étiologiques: interprétation des résultats. In: Epidémiologie. Principes et méthodes quantitatives. Paris: INSERM, 1996: 327-30.